Sign in
Taking peopleNo phase

Histotripsy for Renal Cell Carcinoma

Key facts

Who runs it
The University of Hong Kong
Where
Hong Kong1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
15 people, planned
Started
13 Oct 2026
Expected to end
30 Oct 2029
Type of study
Interventional
Treatments tested
  • HistoSonics® Edison System (US)
Record updated
17 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age ≥ 18 years old
  • Fit for general anaesthesia
  • Histologically confirmed renal cell carcinoma; radiological diagnosis acceptable if biopsy is not feasible
  • With or without distant metastases
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade 0-2
  • Tumour visible and targetable by ultrasound with acceptable acoustic windows
  • Adequate hematologic, hepatic, and renal function (eGFR ≥45mL/min, ≤14 days prior to the planned index procedure date)

Who cannot take part

  • Poor general condition with limited life expectancy
  • Refusal to take part in clinical trial
  • Not fit for general anaesthesia
  • Uncontrolled coagulopathy
  • The treatment of the tumour will not allow for an adequate margin as determined by the investigator

This trial is currently available in Hong Kong.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The project will be a pilot study in localised or metastatic renal cell carcinoma, assessing safety, local control, and exploratory immune endpoints. Outcomes from this work will inform rational combinations with targeted agents and immune checkpoint blockade and may define a new, image-guided, non-invasive modality for renal cell carcinoma. If successful, histotripsy could become a new non-thermal, local therapy for renal cell carcinoma with dual benefits of debulking and immune activation achieving strong clinical and scientific impact.

The group in the trial

  • Patients receiving Histotripsy procedure for renal cell cancer using the HistoSonics® Edison SystemTreatment being tested

    Treatment: HistoSonics® Edison System (US)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Histotripsy for Renal Cell Carcinoma: a Pilot Study for a Novel Focused Therapy With an Unmet Need
Record updated
17 November 2026